|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hagar Labouta, PhD, presents how researchers continue to increase the complexity of their placenta-on-a-chip models and, as their research progresses, they are confident this technology will aid the development of novel therapies to treat a wide range of maternal and fetal conditions.
|
|
|
Betsy Wagner and Marie E. Lamont explain how before anyone can take full advantage of this opportunity, education about the technology and the practical benefits, viewed through the lens of understanding historical lessons learned, will be the critical next step.
|
|
|
Simon Johns says with the US scheduled to implement IDMP this year and the EU in the process of implementation, IDMP is no longer just a distant requirement. It is happening now, and all organizations should be prepared for mandatory use this year.
|
|
|
Ronald Aung-Din, MD, and Chantelle Martin, MBChB, explain how targeting such chronic pain with a fast-acting, non-systemic, convenient, and easy-to-use at-home NeuroDirect ketamine cream could be of significant benefit in patients with CRPS as well as other neuropathic pain states, including chronic neck and back pain.
|
|
|
|
|
|
|
|
|

Labcorp provides industry leading preclinical medical device and combination product testing, as well as consulting and risk assessment solutions to help support you and your device from the earliest stages of study design to GLP assessments. With over 40 years of experience, our 150+ dedicated and highly experienced specialists have deep knowledge of delivering comprehensive preclinical testing, along with regulatory and compliance guidance that will provide you the answers, clarity, and confidence required to accelerate the development of your device or product. Gain efficiencies by leveraging our end-to-end testing portfolio that includes biocompatibility, microbiology/reusability validation, analytical chemistry, efficacy, and surgical services. Let’s work together to give your device a healthy start. Click here for more.
|
|
|
|
|
|
 |
|
Aldena Therapeutics has chosen PCI Pharma Services (PCI) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for….
|
|
 |
|
Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated recently announced Ligand has acquired a 13% portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of….
|
|
 |
|
Ready-for-sterilization (RFS) combiseals for cartridges take the burden off drug manufacturers to prep packaging components for sterilization, saving time and cost while complying with FDA and EU regulations…..
|
|
 |
|
Vetter recently announced additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development…..
|
|
 |
|
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients….
|
|
|
|
|
|
|
|
 |
|
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
|
|
 |
|
Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on
|
|
 |
|
In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….
|
|
|
|
|
|
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …
|
|
 |
|
Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …
|
|
 |
|
Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …
|
|
|
|
|
Upcoming eNewsletter Features:
November 1 – Formulation Development
November 8 – Drug Delivery
|
|
|
|
|
|
|
|